In 2010, the FDA approved the combination drug dextromethorphan/quinidine under the brand name Nuedexta for the treatment of pseudobulbar affect (uncontrollable laughing/crying). Dextromethorphan is the active therapeutic agent in the combination; quinidine merely serves to inhibit the enzymatic degradation of dextromethorphan and thereby increase its circulating concentrations via inhibition of CYP2D6. -- https://en.m.wikipedia.org/wiki/Dextromethorphan#Pseudobulbar_affect
See. You see this. "In 2010." Cytochrome P450 metabolism has been understood and used in drug dev/manufacturing for more than 15 years. I think prescribers should at least be familiar with the terminology and the concept of enzymatic induction/inhibition. They should have to read a couple goddamn Wikipedia pages. I don't think that's too much to ask.
